Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04723706 · ClinicalTrials.gov registry record
Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients
A clinical trial, sponsored by Henry Ford Health System.
- Completed
- Registry status
- 33
- Enrollment target
NCT04723706 is a clinical trial that has completed, run by Henry Ford Health System. The registered enrollment target is 33 participants.
The verdict
NCT04723706 has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
For many patients with hematologic disorders and bone marrow failure, hematopoietic stem cell transplantation (HSCT) or cellular therapy (CART) offers a curative treatment option. Patients after SCT or CART have a variable period of immune deficiency in the post-treatment period. The response to vaccination may affect the outcome of the transplant patients. the immunogenicity of vaccines in this immunosuppressed population is uncertain and variable. HSCT and CAR-T recipients are in a COVID-19 high-risk group and conferring immunity by vaccination at the earliest effective timepoint is desirable. At present, the immunogenicity and efficacy of SARS-CoV-2 vaccines in immune-impaired patients including autologous and allogeneic HSCT recipients is unknown. Furthermore, the impact of GvHD and IST on SARS-CoV-2 vaccine immunogenicity is unknown. the investigators aim to evaluate the vaccination response to COVID vaccines after SCT and CART
Interventions
- DIAGNOSTIC_TEST COVID-19 serology IgG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-03-19 |
| Est. Completion | 2024-01-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04723706
The ClinicalTrials.gov registry entry for NCT04723706 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which COVID-19 serology IgG is the first listed.
NCT04723706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04723706 about?
NCT04723706 is a clinical study titled "Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients". For many patients with hematologic disorders and bone marrow failure, hematopoietic stem cell transplantation (HSCT) or cellular therapy (CART) offers a curative treatment option. Patients after SCT or CART have a variable period of immune deficiency in the post-treatment period. The response to vac...
What is the current status of trial NCT04723706?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2021-03-19. Estimated completion is 2024-01-02.
What interventions are being tested in trial NCT04723706?
The interventions under investigation include: COVID-19 serology IgG (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04723706?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.